MedTrace Logo

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

NCT02976896 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2023-02-16

No results posted yet for this study

Summary

We conduct the phase II clinical trial to further explore the efficacy and safety of Apatinib Mesylate in treating recurrent or metastatic esophageal squamous cell carcinoma after the failure of conventional treatments. An exploratory molecular marker analysis will be performed in order to find out the beneficial population of Apatinib Mesylate.

Conditions

Interventions

DRUG

Apatinib Mesylate

Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.

Sponsors & Collaborators

  • Yuhong Li

    lead OTHER

Principal Investigators

  • Li Yuhong, MD · Sun Yat-sen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2019-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02976896 on ClinicalTrials.gov